Golden Seeds company Day Zero Diagnostics recently revealed a new approach to antimicrobial susceptibility testing using artificial intelligence (AI) to guide analysis. The system, Keynome gAST, analyzes bacterial whole genomes extracted from patient blood samples, eliminating the need for culture growth. Read more here.